Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass-Reference-Cited by-同舟云学术

Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass

Published:2024-01-02 Issue:2 Volume:63 Page:211-225
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Gibert Audrick^ORCID,Lanoiselée Julien,Gouin-Thibault Isabelle,Pontis Adeline,Azarnoush Kasra,Petrosyan Andranik,Grand Nathalie,Molliex Serge,Morel Jérome,Gergelé Laurent,Hodin Sophie,Bin Valérie,Chaux Robin,Delavenne Xavier,Ollier Edouard

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01334-3.pdf

Reference34 articles.

1. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40(4):498–530. https://doi.org/10.2165/00003495-199040040-00003.

2. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(4 Suppl.):258S-S275. https://doi.org/10.1378/chest.108.4_supplement.258s.

3. Hemker HC. A century of heparin: past, present and future. J Thromb Haemost. 2016;14(12):2329–38. https://doi.org/10.1111/jth.13555. (Epub 2016 Dec 16).

4. Bray B, Lane DA, Freyssinet JM, Pejler G, Lindahl U. Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J. 1989;262(1):225–32. https://doi.org/10.1042/bj2620225.

5. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost. 2007;5(5):955–62. https://doi.org/10.1111/j.1538-7836.2007.02477.x.Erratum.In:JThrombHaemost.2007Jun;5(6):1343.